Stock FOUNDATION MEDICINE INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Foundation Medicine Inc

Equities

US3504651007

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bayer : Roche takes on Loxo, Bayer in gene-defined cancer class
RE
Foundation Medicine : Setting the Pace for Blood Tumor Mutational Burden
PU
Foundation Medicine : Publishes New Data in Nature Medicine Supporting Blood Tumor Mutational Burden (bTMB) as a Novel Predictor of Response to Cancer Immunotherapy
BU
Foundation Medicine : and Guardant Health Agree to Settle Patent Infringement Lawsuit
BU
Beyond MSI: Expanding the Reach of Immunotherapy in Colorectal Cancer
PU
WeissLaw LLP: Foundation Medicine, Inc. Acquisition May Not Be In The Best Interest of FMI Shareholders
PR
Citigroup : Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
RE
Foundation Medicine : to Present at Upcoming Investor Conferences
BU
Foundation Medicine : Quantum Leaps for Quantitative Markers
PU
Foundation Medicine : and Collaborators to Present New Data at ASCO 2018 Supporting Comprehensive Genomic Profiling (CGP) to Inform Personalized Approaches in Cancer Care
BU
Foundation Medicine : Establishes Immuno-Oncology Companion Diagnostics Collaboration with Merck
BU
Foundation Medicine : Receives New ADLT Status for FoundationOne CDx™ from the Centers for Medicare and Medicaid Services (CMS)
BU
Foundation Medicine : Announces 2018 First Quarter Results and Recent Highlights
BU
Foundation Medicine : Launches Gene Expression Profiling Program to Identify Known and Novel Biomarkers in Advanced Cancer
BU
Foundation Medicine : Roche and DIAN Diagnostics Collaborate to Advance Personalized Cancer Care in China
BU
Foundation Medicine : New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration
BU
Foundation Medicine : and its Collaborators Present New Findings Supporting Tissue- and Blood-based Comprehensive Genomic Profiling (CGP) to Inform Targeted and Cancer Immunotherapy Treatment Strategies
BU
Cancer Treatment Centers of America : and Foundation Medicine Launch Joint Educational Campaign to Raise Consumer Awareness of Precision Medicine Approaches in Cancer Care
PR
Foundation Medicine : Announces Commercial Availability of FoundationOne CDx™, the First FDA-Approved Comprehensive Genomic Profiling Assay for All Solid Tumors Incorporating Multiple Companion Diagnostics
BU
Foundation Medicine : Announces Final National Coverage Determination (NCD) from the Centers for Medicare & Medicaid Services (CMS), Including Coverage for FoundationOne CDx™ Across All Solid Tumors
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Foundation Medicine Inc